Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma

Documenti analoghi

• Comment on “Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T‐Cell Lymphoma”
  di: Manish R. Bhise, et al.
  Pubblicazione: (2025)
• Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma
  di: Pooneh Soltantabar, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics and Exposure‐Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
  di: Amitava Mitra, et al.
  Pubblicazione: (2026)
• Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma
  di: Per Olsson Gisleskog, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies
  di: Sven Stodtmann, et al.
  Pubblicazione: (2026)